XML 106 R95.htm IDEA: XBRL DOCUMENT
v3.20.2

Segments - Information by Reportable Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | $ 30,424 | $ 32,836 | $ 60,262 | $ 55,421
Segment Adjusted EBITDA | (5,362) | (18,680) | (25,080) | (40,200)
PGEN Therapeutics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Segment Adjusted EBITDA | (5,698) | (7,467) | (12,617) | (14,836)
ActoBio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Segment Adjusted EBITDA | (1,135) | (4,124) | (3,125) | (6,562)
MBP Titan |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Segment Adjusted EBITDA | (5,199) | (9,188) | (13,963) | (17,214)
Trans Ova |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Segment Adjusted EBITDA | 6,528 | 4,932 | 5,329 | 2,706
Human Biotherapeutics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Segment Adjusted EBITDA | (495) | (354) | (1,833) | (577)
All Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Segment Adjusted EBITDA | 637 | (2,479) | 1,129 | (3,717)
Operating segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 30,410 | 32,797 | 60,208 | 55,274
Revenues | 32,109 | 35,997 | 64,407 | 61,568
Operating segments | PGEN Therapeutics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 218 | 549 | 378 | 1,730
Revenues | 1,830 | 2,961 | 4,093 | 6,507
Operating segments | ActoBio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 32 | 181 | 230 | 582
Revenues | 29 | 233 | 227 | 1,077
Operating segments | MBP Titan |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 0 | 1,215 | 0 | 2,696
Revenues | 0 | 1,217 | 7 | 2,698
Operating segments | Trans Ova |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 23,845 | 24,392 | 40,630 | 39,326
Revenues | 23,935 | 25,066 | 40,829 | 40,273
Operating segments | Human Biotherapeutics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 4,210 | 2,462 | 14,573 | 2,845
Revenues | 4,210 | 2,462 | 14,573 | 2,845
Operating segments | All Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues from external customers | 2,105 | 3,998 | 4,397 | 8,095
Revenues | 2,105 | 4,058 | 4,678 | 8,168
Intersegment revenues |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,699 | 3,200 | 4,199 | 6,294
Intersegment revenues | PGEN Therapeutics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,612 | 2,412 | 3,715 | 4,777
Intersegment revenues | ActoBio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | (3) | 52 | (3) | 495
Intersegment revenues | MBP Titan |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 0 | 2 | 7 | 2
Intersegment revenues | Trans Ova |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 90 | 674 | 199 | 947
Intersegment revenues | Human Biotherapeutics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Intersegment revenues | All Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 0 | $ 60 | $ 281 | $ 73

X
- Definition Segment Adjusted EBITDA defined as net income (loss) before (i) interest expense, (ii) income tax expense/benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) write-off of reacquired in-process research and development, (vii) equity in net income (loss) of affiliates, and (viii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. + References No definition available. + Details
Name: | pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pgen_PGENTherapeuticsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pgen_PrecigenActoBioSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pgen_MBPTitanSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pgen_HumanBiotherapeuticsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |